127 filings
EFFECT
ELVN
Enliven Therapeutics Inc
1 May 24
Notice of effectiveness
12:15am
424B3
ELVN
Enliven Therapeutics Inc
30 Apr 24
Prospectus supplement
4:16pm
ARS
2023 FY
ELVN
Enliven Therapeutics Inc
26 Apr 24
Annual report to shareholders
4:16pm
DEFA14A
ELVN
Enliven Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
4:11pm
DEF 14A
ELVN
Enliven Therapeutics Inc
Definitive proxy
26 Apr 24
4:05pm
PRE 14A
hrp62uun
15 Apr 24
Preliminary proxy
4:05pm
8-K
mska cvntn
11 Apr 24
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
8:02am
8-K
lrcjoloex6ptehqtq
9 Apr 24
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
4:14pm
D
9k4br9jg50kyw358
3 Apr 24
$90.00 mm in equity / options / securities to be acquired, sold $90.00 mm, 20 investors
5:07pm
8-K
6a1bx7cwswyuznw6hrul
19 Mar 24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
8:46am
S-8
4wwm n47ss38abw
14 Mar 24
Registration of securities for employees
5:15pm
8-K
zhj1nr 721ec
14 Mar 24
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
4:10pm
8-K
v3k lcygf3
9 Nov 23
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:10pm
8-K
kw5 n97uu1xa3ylq
10 Aug 23
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm
424B5
ujs1 i2sz79cg
6 Jul 23
Prospectus supplement for primary offering
4:06pm
EFFECT
a5z r3l875f
5 Jul 23
Notice of effectiveness
12:15am